Literature DB >> 22744807

Assessment of bone scans in advanced prostate carcinoma using fully automated and semi-automated bone scan index methods.

Yoshiko Takahashi1, Mana Yoshimura, Kunihito Suzuki, Tsuyoshi Hashimoto, Hideji Hirose, Kenji Uchida, Shingo Inoue, Kiyoshi Koizumi, Koichi Tokuuye.   

Abstract

OBJECTIVE: As metastasis of prostate carcinoma occurs in approximately 80 % of terminal prostate carcinoma patients, the prognostic value of the prediction of prostate carcinoma by bone scintigraphy is important. We compared the automated and semi-automated bone scan index (BSI) system with extent of disease (EOD) grade if there is a possibility to substitute for EOD grading.
MATERIALS AND METHODS: We evaluated the bone scintigraphic images of 158 prostate carcinoma patients (mean age, 69.2 years old; range 50-97). Bone scans were obtained approximately 3 h after the intravenous injection of 740 MBq technetium-99 m-methylene diphosphonate. EOD grade was evaluated by 2 experienced radiologists using bone scintigraphy, magnetic resonance imaging, and computed tomography. We calculated the BSI using the Bonenavi(®) system (Fujifilm RI Pharma Co., Ltd.), utilizing data from a Japanese database. The semi-automated BSI of the patients was obtained by modifying the automated BSI independently by 3 radiologists (referred to as "observers" in this study) with 25, 10, and 4 years of experience. We then compared the EOD with the corresponding 4 independent BSIs for each patient. We used the Steel-Dwass test for multiple comparisons of the BSI among different EOD groups of patients. We analyzed the receiver-operating characteristics (ROC) curve to determine the cutoff values of sensitivity and specificity, which were both set at 95 %.
RESULTS: There were significant correlations observed among the mean EOD and BSI scores as determined using the Bonenavi(®) system for every patient group for all observers and the automated method. There was also a statistically significant difference in the mean BSI among all EOD groups (grades 0, 1, or 2-4) for all observers and the automated method. Each ROC curve showed an ideal shape and was within the optimal cutoff range.
CONCLUSION: On the basis of the present results, BSI as calculated using the Bonenavi(®) system significantly correlated with EOD. Sensitivity and specificity as measured by the fully automated method were lower than those of semi-automated BSI with modification by radiologists. Therefore, semi-automated BSI is considered to have the possibility to substitute for EOD grading to predict the survival of prostate carcinoma patients with bone metastases, with only slight interobserver variation.

Entities:  

Mesh:

Year:  2012        PMID: 22744807     DOI: 10.1007/s12149-012-0617-0

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  10 in total

1.  Current state of bone scintigraphy protocols and practice in Japan.

Authors:  Hajime Ichikawa; Kenta Miwa; Koichi Okuda; Takayuki Shibutani; Toyohiro Kato; Akio Nagaki; Hiroyuki Tsushima; Masahisa Onoguchi
Journal:  Asia Ocean J Nucl Med Biol       Date:  2020

2.  Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide.

Authors:  Aseem Anand; Michael J Morris; Steven M Larson; David Minarik; Andreas Josefsson; John T Helgstrand; Peter S Oturai; Lars Edenbrandt; Martin Andreas Røder; Anders Bjartell
Journal:  EJNMMI Res       Date:  2016-03-09       Impact factor: 3.138

3.  Computer-assisted quantitative evaluation of bisphosphonate treatment for Paget's disease of bone using the bone scan index.

Authors:  Satoshi Nagano; Shunsuke Nakamura; Hirofumi Shimada; Masahiro Yokouchi; Takao Setoguchi; Yasuhiro Ishidou; Hiromi Sasaki; Setsuro Komiya
Journal:  Exp Ther Med       Date:  2016-11-14       Impact factor: 2.447

4.  Influence of the Different Primary Cancers and Different Types of Bone Metastasis on the Lesion-based Artificial Neural Network Value Calculated by a Computer-aided Diagnostic System, BONENAVI, on Bone Scintigraphy Images.

Authors:  Takuro Isoda; Shingo BaBa; Yasuhiro Maruoka; Yoshiyuki Kitamura; Keiichiro Tahara; Masayuki Sasaki; Masamitsu Hatakenaka; Hiroshi Honda
Journal:  Asia Ocean J Nucl Med Biol       Date:  2017

5.  Radium-223 for primary bone metastases in patients with hormone-sensitive prostate cancer after radical prostatectomy.

Authors:  Vera Wenter; Annika Herlemann; Wolfgang P Fendler; Harun Ilhan; Natalia Tirichter; Peter Bartenstein; Christian G Stief; Christian la Fougère; Nathalie L Albert; Axel Rominger; Christian Gratzke
Journal:  Oncotarget       Date:  2017-07-04

6.  Skeletal standardized uptake values obtained by quantitative SPECT/CT as an osteoblastic biomarker for the discrimination of active bone metastasis in prostate cancer.

Authors:  Ichiei Kuji; Tomohiko Yamane; Akira Seto; Yota Yasumizu; Suguru Shirotake; Masafumi Oyama
Journal:  Eur J Hybrid Imaging       Date:  2017-10-12

Review 7.  Assessment of Skeletal Tumor Load in Metastasized Castration-Resistant Prostate Cancer Patients: A Review of Available Methods and an Overview on Future Perspectives.

Authors:  Francesco Fiz; Helmut Dittman; Cristina Campi; Silvia Morbelli; Cecilia Marini; Massimo Brignone; Matteo Bauckneht; Roberta Piva; Anna Maria Massone; Michele Piana; Gianmario Sambuceti; Christian la Fougère
Journal:  Bioengineering (Basel)       Date:  2018-07-28

8.  Systematic review & meta-analysis of positron emission tomography/computed tomography and bone scan in the diagnosis of prostate lesions.

Authors:  Jiafu Wang; Yue Han; Lin Lin; Linhan Zhang; Jin Li; Huiqi Gao; Peng Fu
Journal:  Transl Androl Urol       Date:  2021-11

9.  Distribution Features of Skeletal Metastases: A Comparative Study between Pulmonary and Prostate Cancers.

Authors:  Changyin Wang; Ying Shen; Shaobo Zhu
Journal:  PLoS One       Date:  2015-11-23       Impact factor: 3.240

10.  Novel diagnostic model for bone metastases in renal cell carcinoma patients based on bone scintigraphy analyzed by computer-aided diagnosis software and bone turnover markers.

Authors:  Takeshi Ujike; Motohide Uemura; Taigo Kato; Koji Hatano; Atsunari Kawashima; Akira Nagahara; Kazutoshi Fujita; Ryoichi Imamura; Norio Nonomura
Journal:  Int J Clin Oncol       Date:  2022-02-04       Impact factor: 3.402

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.